Objective: The purpose of this study was to assess regional recurrence rates of patients who underwent sentinel lymph node biopsy (SLNB) using radiocolloid guidance alone. Background: Isosulfan blue dye is commonly used along with Tc99-labeled radiocolloid localization in SLNB for melanoma. Blue dye has, however, been associated with allergic reactions, long-term staining of skin, and increased cost. We hypothesized that the rate of regional recurrence when SLNB is performed with radiocolloid alone would be comparable to established reports using both radiocolloid and blue dye. Methods: A prospectively collected database was retrospectively queried for patients who underwent SLNB for melanoma during the years 2005 through 2008. Data collected included patient demographics, primary lesion characteristics, operative details, and recurrence. The primary outcome was the rate of recurrence within the biopsied basin after negative SLNB's performed without isosulfan blue dye. Results: In 215 patients, 279 nodal basins were identified. All patients underwent successful radiocolloid localization, and positive sentinel nodes were found in 40 patients (18.6%). Six of 175 patients with a negative SLNB developed a regional node recurrence as the first site of metastasis (3.4%). Among all 215 patients, 44 experienced recurrence of any kind (20.5%). Higher mitotic rate and Breslow depth were significantly associated with likelihood of recurrence. Conclusions: Success rates, node positivity rates, and rates of regional recurrence after SLNB for melanoma using radiocolloid alone are acceptable and similar to those of prior reports using blue dye plus radiocolloid.
S ince its original description in 1992, sentinel lymph node biopsy (SLNB) has become a vital component of the staging protocol for melanoma. 1 More than any patient demographic or tumor characteristic, the most powerful prognostic indicator in early-stage melanoma is the status of the sentinel node. 2 Sentinel node localization in melanoma was originally described using vital dyes to permit intraoperative mapping. Using this technique alone, node localization rates ranged from 52% to 95%. 3 By the late 1990 s, the addition of radiolabeled colloids led to localization rates of 98% to 99%. [4] [5] [6] [7] [8] Within this body of work, radiocolloid guidance alone had a sentinel node localization failure rate of 2% to 5%, indicating a continuing role for blue dye. 7, 9 Over the past decade, there has been mounting evidence that visual localization using blue dye may not confer a clinically meaningful benefit over radioguidance alone. [10] [11] [12] [13] In the setting of breast cancer, compared with radioguidance alone, the combined modality of blue dye plus radioguidance confers only a 2% localization rate advantage. 14, 15 Juxtaposed against this marginal benefit are rare but potentially serious adverse events associated with blue dye, including prolonged cutaneous staining, 3 skin reactions, and anaphylaxis rates ranging from 0.1% to 2.7%. [16] [17] [18] [19] Finally, because Medicare does not allow for separate reporting of vital dye injection for reimbursement, its routine use may also incur unnecessary costs to the provider.
Whether the increased sentinel node localization rate conferred by blue dye results in clinically meaningful benefit is unclear. The purpose of this study is to report recurrence outcomes among patients with melanoma who undergo SLNB without blue dye. We hypothesized that SLNB with radioguidance alone would result in node positivity and regional recurrence rates that are comparable to existing reports of combination localization modalities.
METHODS
We conducted a retrospective review of a prospectively collected database of consecutive patients with primarily trunk and extremity melanoma who underwent SLNB from January 2005 to December 2008 for primary cutaneous melanoma at our institution. During this period, patients received SLNB if their primary cancer had a Breslow thickness of 1.0 mm or more, Clarks level of 4 or higher, had high-risk characteristics such as ulceration, or had a positive deep margin on shave biopsy. Between 2005 and 2007, selected patients with thin melanomas (<1.0 mm) with regression also were offered SLNB. 20 After surgery, patients underwent followup visits every 4 to 12 months (depending on overall risk) during the first 2 years, every 6 to 12 months to year 5, then annually thereafter. Patients were identified from a prospectively collected clinical database approved for research use (IRB 10803). For all patients, data were accrued on demographics, cancer characteristics, length of follow-up, pathology results, and recurrence outcomes. Operative characteristics, including node and background radioactivity counts, were determined by retrospective chart review.
Patients received preoperative lymphoscintigraphy using Technetium 99m-labeled sulfur radiocolloid injected intradermally at the site of prior biopsy on the morning of surgery or the afternoon of the prior day. Lymphoscintigraphy images were made available to the surgeon to determine the surgical approach to regional lymphatic drainage basins. Intraoperatively, a handheld gamma probe was used to guide the placement of biopsy incisions and to localize radioactive nodes. For each excised node, an ex vivo radioactivity count was recorded. Biopsy criteria followed the 10% guideline, meaning nodes were excised until the resection bed contained a residual radioactivity level less than 10% that of the ''hottest'' node removed. The removed nodes were considered to be the sentinel nodes within the dissected basin. Two patients did not receive preoperative lymphoscintigraphy imaging due to scheduling difficulties. Two additional patients received preoperative lymphoscintigraphy, but no lymphatic drainage was visualized on preoperative images. These patients' operations were guided solely by intraoperative localization using the gamma probe. For 2 more patients, the gamma probe was not available upon incision; thus, intradermal injection of 1.5 mL Lymphazurin blue dye was used for visual localization of sentinel nodes. These 2 were the only patients who received blue dye guidance over the study period. However, for both patients, the gamma probe became available at the time of node extraction, and nodes were removed on the basis of radioactive criteria. For 33 of 215 patients (15.3%), the 10% criterion for residual bed radioactivity was not satisfied, despite diligent dissection.
After removal, all excised sentinel nodes were submitted for pathologic analysis: each node was serially partitioned into sections 1-mm thick. Sections were examined using hematoxylin and eosin staining. Immunohistochemistry (IHC) using antibodies to MART-1/ Melan A, S-100, Tyrosinase, or gp100 (HMB45) was performed at the discretion of the supervising dermatopathologist. Patients who had a tumor-positive sentinel lymph node were offered completion lymphadenectomy. We defined a false-negative outcome as recurrence in a nodal basin, which was previously negative for metastases during the original SLNB (regional recurrence). Recurrences within 5 cm of the primary cancer site were considered local, whereas those located between the excision site and the mapped nodal basin were considered in-transit.
For statistical analyses, Breslow depth was discretized to 2 mm or less and more than 2 mm on the basis of the American Joint Committee on Cancer staging system, and mitotic rate was discretized on the basis of sample median. To determine clinical and pathologic factors associated with overall survival and recurrence of any type, univariate analyses were performed using the Fisher exact test for categorical variables. Multivariate analysis using logistic regression was performed for factors associated with recurrence on univariate analysis. Kaplan-Meier curves and the log-rank test for significance are used to show recurrence-free survival. Multivariate analyses for overall survival were not performed because of a low rate of death (N ¼ 27). For all statistical analyses, P < 0.05 were considered significant, and calculations were performed using SAS statistical software (version 9.3; SAS Institute, Inc, Cary, NC). This study was approved by the University of Virginia Institutional Review Board (IRB-HSR protocol 17273).
RESULTS
A total of 215 patients were included in the analysis. Clinicopathologic characteristics of the patient population are shown in Table 1 . Median length of follow-up was 4.2 years [interquartile range (IQR): 1.2-6.1]. Median Breslow thickness was 1.56 mm (IQR: 1.01-2.57). The majority of primary cancers were located on the trunk (51.6%, 111/215).
One or more sentinel nodes were excised from every targeted lymphatic basin (100% success at node localization), totaling 545 nodes removed from 279 basins ( Table 2 ). An average of 2 nodes were removed per basin (IQR: 1-3). Forty patients had at least 1 sentinel node positive for metastasis (18.6%). Of these, 32 (80%) subsequently underwent completion lymphadenectomy, 7 (22%) of which yielded additional positive nodes.
Overall, 44 patients (20.5%) experienced recurrence after a median of 1.9 years (IQR: 0.87-2.9). Under univariate analysis, cancer recurrence was significantly associated with Breslow depth of more than 2 mm, Clark level of 4 or higher, mitotic rate greater than 2 per mm 2 , and positive SLNB ( Table 3 ). Residual counts exceeding 10% of the count of the hottest node was not associated with recurrence at the univariate level. After incorporating significant risk factors from the univariate model into a logistic multivariate model, only mitotic rate and Breslow depth were significantly associated with cancer recurrence (Fig. 1 ). Analyses were also repeated treating Breslow depth and mitotic rate as continuous variables, in which case both factors were significant predictors of recurrence at the univariate level, but only mitotic rate proved significant on multivariate analysis (data not shown). Over the study period, the mortality rate was 12.6% (27/215), with a 3-year survival rate of 83%. The only risk factor significantly associated with overall mortality at the univariate level was positive SLNB status (38.2% vs 8.3%, P < 0.001). Recurrences occurred in 20% (35/175) of patients who had a negative SLNB result. These included 2 local, 8 in-transit, and 19 distant recurrences. There were 6 (3.4%) regional node recurrences, which were considered false negatives. Three of these occurred in axillary basins, whereas the other 3 were in groin basins. Thus, the negative predictive value of SLNB was 96.6% (169/175), and the false negative rate was 13.0% [6/(40þ6) ]. Six patients presented with recurrence in more than 1 location.
During surgery, the residual radioactivity count in the node basin was less than 10% of the count of the hottest sentinel node for 246 of 279 basins (88%). Thirty-three basins did not satisfy the 10% guideline (12%); the most commonly cited reason within operative records was risk of injury to adjacent structures (nerves, vasculature) with further dissection, in the setting of having removed the dominant hot node(s) identified by lymphoscintigraphy. The distribution of these basins was similar to the overall distribution of the study: 17 axillary basins (51.5%), 9 groin basins (27.3%), 3 head and neck basins (9.1%), and 4 other basins. None of the patients in this subgroup experienced regional recurrence.
DISCUSSION
To maximize success rate and to minimize false negatives, SLNB is traditionally performed using a combination of radiocolloid and visual localization with a vital blue dye. This study demonstrates that SLNB performed using radiocolloid guidance alone may result in a high biopsy success rate and negative predictive value. By excluding blue dye from the operation, providers can avoid skin complications and rare but serious allergic reactions. Although anaphylactic reactions can be easily managed under general anesthesia, omitting blue dye may support SLNB under local anesthesia, which offers advantages in cost and safety. 21, 22 The recurrence patterns within our results are concordant with several collections of multi-institutional data. Early work by Gershenwald et al noted a regional recurrence rate of 5.8% in a population that closely resembles our data set, with a 16% positive sentinel node rate and median Breslow thickness of 1.6 mm. 23 More recently, the Sunbelt Melanoma Trial, the Multicenter Selective Lymphadenectomy Trial, and others have reported regional recurrence rates in previously negative node basins ranging from 2.7% to 4.8%. [24] [25] [26] [27] These studies involve strict protocols that dictate combination localization techniques. Our data showing a regional recurrence rate of 3.4% demonstrate that comparable sampling accuracy is attainable without the additional cost and risk of blue dye.
Several works have scrutinized the expected utility of blue dye localization in the setting of melanoma. As early as 2004, Gipponi reported that, among 126 patients receiving a combination localization protocol, blue dye did not confer additional localization benefit to radioguidance. 10 With a similar combination protocol involving a newer radiocolloid, Sondak et al 13 reported a 100% detection rate of tumor-positive sentinel nodes by radioguidance, compared to 80% by blue dye. In a larger retrospective study, Liu et al compared radiocolloid alone (n ¼ 581) with radiocolloid plus blue dye (n ¼ 571). The miss rates of positive sentinel nodes were 2% and 1% in these 2 groups, respectively (P ¼ 0.56). The authors concluded that there is no significant impact of adding blue dye in terms of the identification of sentinel nodes or in the miss rate of positive nodes. 11 Surgeons in that study adopted the radiocolloid-only technique as they became more comfortable with it; however, that study did not address clinical outcomes. An early large multicenter trial of sentinel node biopsy, in which we participated, reported recurrence outcomes with radiocolloid with or without blue dye, but did not focus on the long-term outcomes without blue dye. 12 To our knowledge, no study has reported clinical results of adopting a radioguidance-only biopsy protocol. The results from our study corroborate existing data, and support our hypothesis that, among experienced surgeons, biopsy using radiocolloid alone yields regional recurrence rates comparable to established reports using both radiocolloid and blue dye. There may be indications, however, for using blue dye in select patients. When a gamma probe is unavailable, blue dye localization is superior to no guidance. Combined localization could also potentially reduce operative duration by facilitating visualization. Finally, when complex anatomy is anticipated, particularly for previously dissected or irradiated basins within the head and neck, blue dye or SpectCT imaging may help focus the dissection and reduce risk of nearby injury. More recently, near-infrared fluorescence imaging has emerged as an attractive alternative to blue dye for real-time visual localization of sentinel nodes within surrounding anatomy. Much like blue dye, fluorescence imaging is best used in conjunction radiocolloid localization due to tissue attenuation of signal. Fluorescence imaging is relatively inexpensive compared to isosulfan blue and has not been reported to cause anaphylaxis. 28 Recent reports suggest that its accuracy in sentinel node detection is 88% to 97% within a variety of nodal basins, superior to that of isosulfan blue. [29] [30] [31] As this innovative technology continues to be explored, we anticipate that its implementation will especially benefit providers who frequently perform SLNB for head and neck melanomas and those who perform SLNB at lower volumes.
A randomized prospective trial would be needed to test the added value of blue dye definitively, but this is not likely to be performed. As a single-institution nonrandomized case series, this study has inherent limitations. First, routine performance of IHC may increase detection of micrometastases. However, serial sectioning through the node is expected also to add value over bivalving the node. In this setting, the added utility of IHC over hematoxylin and eosin staining and optional IHC is not known, and it is an area of interest for future study. 32, 33 Furthermore, criteria for offering SLNB were fluid over our study period as pervading evidence regarding the prognostic value of regression and Clark level continued to mature. 20, 34 Our multivariate analysis assessing for predictors of recurrence was limited by study size to 4 risk factors. We found that tumor thickness and mitotic rate are associated with recurrence, in concordance with prior studies. [35] [36] [37] It is therefore relevant that our study population's median Breslow thickness (1.56 mm) is slightly lower than those in recent trials incorporating blue dye and radiocolloid localization, which have ranged from 1.6 to 1.8 mm. 26, 27, 36 Although positive SLNB status was strongly associated with recurrence on univariate analysis, the association was not significant after accounting for mitotic rate and Breslow depth. Despite this, SLNB status was predictive of overall survival, and we anticipate that in larger data sets, the capacity of SLNB to predict recurrence would likely prove significant. Finally, 11.8% (33/279) of the biopsied basins in our study had residual radioactivity greater than 10% that of the hottest node. Our protocol is to follow the 10% guideline, but with exceptions when the residual bed count seemed to represent nonsentinel secondary nodes and all hot spots seen on lymphoscintigraphy had been accounted for, 38 especially when the residual bed counts are very close to 10%. Within our study, no patient whose operation violated the 10% guideline developed regional recurrence. However, abiding by this guideline can reduce the false-negative rate associated with SLNB, 11, 39 and we do not recommend routine indifference toward this important guideline.
CONCLUSIONS
Although most reports of sentinel lymph node biopsy employ combined radioguidance and visual localization, radioguidance alone yields a high sentinel node-sampling rate. Our regional recurrence rate in node-negative basins is in the range that has been reported in other large studies with blue dye plus radiocolloid. Blue dye is visible through thin layers of tissue, but not through the skin or deep in node-bearing basins. Also, radiocolloid, but not blue dye, is retained in the sentinel nodes for many hours and can be reliably detected over time. Isosulfan blue can cause anaphylaxis and carries added costs; thus, successful localization without it can be advantageous for the patient and for the health system. Prior reports show that blue dye does not increase detection of tumor-positive nodes. 10, 11 The present report corroborates those findings and presents supportive clinical outcomes data. By forgoing blue dye guidance, experienced surgeons may anticipate reliable nodal sampling while avoiding unnecessary costs and risks.
